TY  - BOOK
AU  - Lessin, Lawrence S
TI  - Inflammatory plasma markers and pancreatic cancer risk: a prospective study of five U.S. cohorts
SN  - 1055-9965
KW  - *Inflammation/bl [Blood]
KW  - *Pancreatic Neoplasms/bl [Blood]
KW  - *Tumor Markers, Biological/bl [Blood]
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - C-Reactive Protein/me [Metabolism]
KW  - Case-Control Studies
KW  - Cohort Studies
KW  - Female
KW  - Humans
KW  - Inflammation/ep [Epidemiology]
KW  - Interleukin-6/bl [Blood]
KW  - Male
KW  - Middle Aged
KW  - Pancreatic Neoplasms/ep [Epidemiology]
KW  - Prospective Studies
KW  - Randomized Controlled Trials as Topic
KW  - Risk Factors
KW  - United States/ep [Epidemiology]
KW  - Washington Cancer Institute
KW  - Journal Article
KW  - Research Support, N.I.H., Extramural
KW  - Research Support, Non-U.S. Gov't
N2  - Chronic inflammation may play a role in the development of pancreatic cancer. However, few prospective studies have examined the association between plasma inflammatory markers and pancreatic cancer risk. Therefore, we investigated the association of prediagnostic circulating C-reactive protein (CRP), interleukin-6 (IL-6), and TNF-alpha receptor II (TNF-alphaR2) with subsequent pancreatic cancer risk in a prospective, nested case-control study of 470 cases and 1,094 controls from Health Professionals Follow-up Study, Nurses' Health Study, Physicians' Health Study, Women's Health Initiative, and Women's Health Study. The median follow-up time of cases was 7.2 years (range 1-26 years). No association was observed between plasma CRP, IL-6, and TNF-alphaR2 and the risk of pancreatic cancer. Comparing extreme quintiles, the multivariate ORs were 1.10 [95% confidence interval (CI), 0.74-1.63; Ptrend = 0.81] for CRP, 1.19 (95% CI, 0.81-1.76; Ptrend = 0.08) for IL-6, and 0.88 (95% CI, 0.58-1.33; Ptrend = 0.57) for TNF-alphaR2. In conclusion, prediagnostic levels of circulating CRP, IL-6, and TNF-alphaR2 were not associated with the risk of pancreatic cancer, suggesting that systemic inflammation as measured by circulating inflammatory factors is unlikely to play a major role in the development of pancreatic cancer
UR  - http://dx.doi.org/10.1158/1055-9965.EPI-12-1458
ER  -